A B S T R A C T 2-n-Butyl-3-(4'-diethylaminoethoxy-3',5'-diiodobenzoyl) -benzofurane (amiodarone), a drug used in arrythmias and angina pectoris, contains 75 mg of organic iodine/200 mg active substance. Four studies were performed to test its effect on thyroid hormone metabolism: (a) nine male subjects were treated with 400 mg of amiodarone for 28 days; (b) five male subjects received, for the same period of time, 150 mg of iodine in the form of Lugol's solution; (c) five subjects received 300 Ag L-thyroxine (T4) for 16 days; from the 10th to the 16th day, 400 mg of amiodarone was added; and (d) five euthyroid subjects received 300 Ag L-T4 for 16 days. The changes in serum thyroid-stimulating hormone (TSH), serum total T4, 3,5,3'-triiodothyronine (T3), free T3, and 3,5',3'-triiodothyronine (reverse Ta, rT3) were measured, and the pituitary reserve in TSH was evaluated by a thyrotropin-releasing hormone (TRH) test.
16 days. The changes in serum thyroid-stimulating hormone (TSH), serum total T4, 3,5,3'-triiodothyronine (T3), free T3, and 3,5',3'-triiodothyronine (reverse Ta, rT3) were measured, and the pituitary reserve in TSH was evaluated by a thyrotropin-releasing hormone (TRH) test.
The results show that amiodarone induced a decrease in serum Ta (28±5.1 ng/100 ml, mean ±SEM, P < 0.05), whereas serum T4 and rTs increased (1.4± 0.4 /g T4/100 ml, NS and 82.7±9.3 ng rTs/100 ml, P < 0.01). The control study with an equal amount of inorganic iodine did not induce these opposite changes but slightly lowered serum rTs, T3, and T4. In the third study, serum rTs increased as under amiodarone treatment, thereby proving that these changes were peripheral.
It is suggested that amiodarone changes thyroid hormone metabolism, possibly by reducing deiodination of T4 to Ts and inducing a preferential production of rT3.
INTRODUCTION
2-n-Butyl-3-(4'-diethylaminoethoxy-3',5'-diiodobenzoyl) -benzofurane (amiodarone)1 is an antiarrythmic and antianginal drug used widely on the European continent ( 1 ).
It contains 75 mg iodine/200 mg active substance, the average daily dose being 400-600 mg. In view of its high iodine content, the drug was selected to study its influence on thyroid function. In particular, its effect on the metabolism of thyroxine (T4)' was studied, with serum 3,5,3' triiodothyronine (Ts) and 3,3',5' triiodothyronine (reverse Ts; rTa) as the peripheral products of T4 metabolism. It was found that this drug reduced serum T3 and increased serum rT3 and T4. To prove that its effect was peripheral, the study was repeated in T4-treated subjects. within and interassay variability was 6 and 8%, respectively.
METHODS
TSH was also determined by radioimmunoassay (7). The thyroxine-binding globulin capacity for T4 was measured according to Roberts and Nicolai (8) . The normal values (mean±2 SD) for serum T4 were 8.2±3.9 jug/100 ml, for T3 165+46 ng/100 ml, and for rTs 45±20 ng/100 ml. The fraction of serum free T3 was determined by equilibrium dialysis, the normal value being 0.169±0.11% (9) . The normal range for serum TSH was from < 0.5 to 6 ,.U/ml. Statistical analysis. The results were expressed as the mean±+SEM. Significance was calculated by the paired Student's t test and one-way analysis of variance (10) . RESULTS Ly of treat-In vivo and in vitro, amiodarone did not alter the re-, and blood sults of the Ta, rTs, and T4 radioimmunoassays. In vitro, received 13 up to 50 lAg/100 ml amiodarone was without any effect wice a day. on the three assays. To test its influence in vivo, a hymg. The pothyroid subject, treated by a single morning dose of with amio-100 ug T3 (Cytomel Smith Kline & French Laborad with the tories, Philadelphia), received 400 mg amiodarone per re subjects day for 6 days. The fasting serum T3 concentration vaaboratories, ried slightly (220 before and 195 ng Ts/100 ml after 6 )r 10 days days of treatment), and the serum rTs remained unBlood was measurable. The thyroxine-binding globulin capacity was e 4, and 6 measured in the sera of the subjects receiving 300 ,ug 12, 14 , and L-Ti and 400 mg amiodarone. It remained unchanged TRH test (18+0.8 before and 17.1±+1 ,ug T4/100 ml on the 6th were given day of treatment). Hence methodological artifacts due ned a'tthe to the drug were excluded. and amio-
The subjects did not report side effects, and clinical examination did not reveal any modification in thyrs of serum roid size. Pulse rate and rectal temperature did not ietal.s(e) change in the group receiving L-T4 and amiodarone. A (6) . The slight corneal deposit developed in one subject. The ,onse 2 SD lesion had disappeared 3 mo after stopping the drug. )0 ml. The 5 mo after ending the treatment, one 26-yr-old subject developed marked hyperthyroidism of 2-3 mo du-O ml ration. The disease disappeared without treatment.3 Study with amiodarone alone. These studies are shown in Fig. 1 were measured 11 days before and 2 and 28 days after commencement of treatment. They were 0.138±0.06%, 0.136±0.1%, and 0.136±0.07%, respectively (NS). The converse changes were seen with serum rTa. Its serum concentration increased immediately with amiodarone treatment. 28 days later, the serum rTs had increased by 82.7±9.3 ng/100 ml (P < 0.01). The concentration was 2.2 times higher than before treatment and well above the normal range. The serum T4 concentration dropped during the first days of treatment and increased slightly thereafter. By the 28th day the increase was 1.4±0.4 /g/100 ml. Serum TSH increased in the first 6 days of treatment and then returned to initial serum concentrations (Table I) . A marked and significant increment in the TSH response to TRH was seen under amiodarone treatment ( Fig. 2) . The difference between the mean basal and the highest TSH concentration (A max TSH) was 32±4.5 /AU/ml, compared to 20±3 ,uU/ml during the control phase. The increased TSH secretion resulted also in a greater rise of serum T3. The mean absolute increase in T3 (A max Ts) was 47±7.4 compared to 83±+13 ng/100 ml under treatment (P < 0.05).
Study with Lugol's solution (Fig. 3) . Inorganic iodine induced a rapid fall in serum T3 and, to a minor extent, in serum T4 and rT3. Serum Ts remained low for the first 6 days. Later its concentration tended to increase and after 28 days of treatment, exceeded even the initial serum concentration. There was no significant difference between the control and experimental period. FIGURE 4 Effect of 400 mg amiodarone on thyroid hormone serum concentrations in T4-substituted subjects (300 pAg L-T# daily). The solid curves represent the amiodaronetreated group, the interrupted ones the control group treated with 300 ,ug T4 only. For symbols see Fig. 1 . Notice that serum T4, T3, and rTs continued to increase until day 16 under T4 treatment only, an indication that equilibrium was not attained. The serum hormone levels of the amiodarone study and the one with Lugol's solution were compared by one-way analysis of variance. During the control period, there was no significant difference between the two experimental groups. During the treatment, serum Ts levels were not statistically different in the two groups, while serum T4 and rTs values of the group treated with amiodarone were significantly increased (P < 0.01). On the 28th day of amiodarone treatment, mean serum rT3 concentration was 118 ng/100 ml and serum T4 was 3 &g/100 ml above the corresponding mean serum hormone levels during treatment with Lugol's solution.
Study with combined L-T4 and amiodarone treatment. The short-term pretreatment with L-T4 did not allow attainment of equilibrium. The hormone measurements had to be compared to the control group of six subjects substituted with T4 only. The results of both groups are shown in Fig. 4 . Amiodarone (solid lines) had the most marked influence on serum rT3, which increased rapidly and to a similar extent, as with amiodarone alone (55± 7 ng/100 ml compared to 51±10 ng/100 ml with amiodarone alone, see Fig. 1 ). The comparison by one-way analysis of variance with the serum rT3 in the control group showed a significant difference (P < 0.05). Serum T3 levels had a slight but nonsignificant tendency to fall during amiodarone treatment, yet the comparison of these serum T3 levels with the control group showed them to be very significantly lower (P < 0.01). For serum T4, on the other hand, the increase with amiodarone treatment was only slightly greater than in the control group (P = 0.1). On the 6th day of amiodarone treatment, the mean serum T4 was 1.2 ,ug/100 ml above, serum T3 28 ng/100 ml below, and serum rTs 49 ng/100 ml above the control group. Serum TSH remained unmeasurable throughout the 2 h after the TRH injection. DISCUSSION Serum T3 and rTs can vary independently from the serum T4 concentration. In particular, low serum Ts and increased serum rT3 concentrations have been encountered in the newborn, in acute and chronic diseases, and during fasting (11) (12) (13) (14) . Amiodarone induces changes in serum hormone concentrations similar to those during fasting. It is unlikely that these changes are the result of competition between the drug and the thyroid hormones for serum protein-binding sites. In such cases, free hormone fraction would increase while the total serum hormone concentration would decrease. In the present study, serum T3 decreased, and the free fraction of T8 also had a tendency to decrease. The latter finding excludes an effect of competition between amiodarone and T3 for thyroxine-binding globulin. Furthermore, serum T4 and rT3, both of which bind to thyroxine-binding globulin, increased considerably (15) . In addition, any in vivo or in vitro interference of the drug or one of its metabolites in the radioimmunoassays was excluded.
We therefore investigated whether the drug could interfere in thyroid hormone metabolism. For this purpose, two studies were performed. In the first, amiodarone was given for 28 days to euthyroid subjects. In the second, thyroidal secretion was completely suppressed with a slightly supraphysiological dose of T4 (300 ug/ day). In the first study the most marked changes occurred during the initial 6 days of treatment. The risk of side effects was therefore reduced in the second study by giving amiodarone from the 10th to the 16th day of L-T4 treatment. The control studies consisted of 28 days of treatment with Lugol's solution and 16 days of L-T4 treatment.
The most remarkable effect of amiodarone was the rapid increase in serum rT3, practically identical in the euthyroid and in the T4-substituted subjects. For serum T3 there was an apparent discrepancy between the two groups, as in the T4-substituted subjects T8 did not decrease. Nevertheless, in the T4-substituted group, amiodarone inhibited the increase of serum T3 seen in the respective control group. The difference in serum T3 between the euthyroid and the T4-substituted subjects treated with amiodarone was therefore minor. It can be explained by the excess iodide freed during the metabolism of the drug. Iodide is known to block thyroidal secretion (16) . The decrease of serum Ts and to a minor extent of serum T4 during treatment with Lugol's solution are in keeping with this concept. Hence, it is likely that the serum hormone changes in the euthyroid subjects treated with amiodarone depended on two factors: iodide and the drug itself. The amiodarone effect can therefore best be seen in the T4-substituted group. These experiments suggest that the production of serum Ts decreased while the metabolism of serum T4 was diverted to rTs. In other words, it is postulated that the conversion of T4 to T3 can be blocked partly by amiodarone. Other substances have been postulated to interfere at this step, for instance propylthiouracil, thyroid hormone analogues, and possibly butyl-4-hydroxy-3,5-diiodobenzoate (17/20) . Therefore, it is interesting to compare the structure of amiodarone with T4, to which it has some similarities (Fig. 5) . Amiodarone could compete with T4 for the deiodinative site, or other mechanisms may be involved, such as changes in clear-ance rates and distribution space of T4 and its metabolites.
Amiodarone treatment also caused changes in serum TSH concentrations. As in earlier experiments with iodine treatment, there was a transient rise in serum TSH, and the response of TSH to TRH was increased when compared to a control period (21) . Nevertheless, there was one difference between these experiments and the present study: the response of T3 in the TRH test was previously observed to be inhibited by iodine treatment, while in the present study serum T3 increased nearly twice as much as in the control TRH test, excluding any important blocking effect of this drug on thyroid hormone secretion. The pituitary, on the other hand, sensed the decrease in serum T3 and responded differently. The end-organ response to Ts and also to T4 may therefore be of crucial importance.
